Structure activity relationship studies on Amb639752: toward the identification of a common pharmacophoric structure for DGKα inhibitors

Research output: Contribution to journalArticlepeer-review

Abstract

A series of analogues of Amb639752, a novel diacylglycerol kinase (DGK) inhibitor recently discovered by us via virtual screening, have been tested. The compounds were evaluated as DGK inhibitors on α, θ, and ζ isoforms, and as antagonists on serotonin receptors. From these assays emerged two novel compounds, namely 11 and 20, which with an IC50 respectively of 1.6 and 1.8 µM are the most potent inhibitors of DGKα discovered to date. Both compounds demonstrated the ability to restore apoptosis in a cellular model of X-linked lymphoproliferative disease as well as the capacity to reduce the migration of cancer cells, suggesting their potential utility in preventing metastasis. Finally, relying on experimental biological data, molecular modelling studies allow us to set a three-point pharmacophore model for DGK inhibitors.
Original languageEnglish
Pages (from-to)96-108
Number of pages13
JournalJournal of Enzyme Inhibition and Medicinal Chemistry
Volume35
Issue number1
DOIs
Publication statusPublished - 2020

Keywords

  • Diacylglycerol kinase
  • enzyme assays
  • kinase inhibitors
  • molecular modelling
  • structure–activity relationship

Fingerprint

Dive into the research topics of 'Structure activity relationship studies on Amb639752: toward the identification of a common pharmacophoric structure for DGKα inhibitors'. Together they form a unique fingerprint.

Cite this